



04-14-03

1632

EXPRESS MAIL NO. EV207705019US

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**(To be used for all correspondence
after initial filing)

Application Number	10/025,380
Filing Date	December 19, 2001
First Named Inventor	Jiangchun Xu
Group Art Unit	1632
Examiner Name	Shin Lin Chen
Attorney Docket No.	210121.471C14

RECEIVED

APR 15 2003

ENCLOSURES (check all that apply)

TECH CENTER 1600/2900

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Amendment/Response	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> After Final	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement; Form PTO-1449	<input type="checkbox"/> Declaration	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Cited References	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	_____
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Terminal Disclaimer	_____
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53	<input type="checkbox"/> Small Entity Statement	_____
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Request for Refund	_____

Remarks**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Individual Name	Julie A. Urvater, Ph.D., Patent Agent Reg. No. 50,461
-----------------	--



00500

PATENT TRADEMARK OFFICE

Signature	<i>Julie Urvater</i>
-----------	----------------------

Date	April 11, 2003
------	----------------

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	
-----------------------	--

Signature		Date:
-----------	--	-------



EXPRESS MAIL NO. EV207705019US
PATENT

#80
Dec
4/17/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jiangchun Xu et al.
Application No. : 10/025,380
Filed : December 19, 2001
For : COMPOUNDS FOR IMMUNOTHERAPY AND DIAGNOSIS OF
COLON CANCER AND METHODS FOR THEIR USE

Examiner : Shin Lin Chen
Art Unit : 1632
Docket No. : 210121.471C14
Date : April 11, 2003

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

Box Non-Fee Amendment
Commissioner for Patents
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

Commissioner for Patents:

In response to the Restriction Requirement dated March 12, 2003, Applicants hereby elect Group III, claims 5 and 11-13, directed to an isolated antibody or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2, a composition comprising said antibody, and a method for stimulating an immune response or treating a cancer in a patient with said composition, for examination at this time. Applicants further elect species SEQ ID NO.1081, referred to as C888P, encoded by the cDNA set forth in SEQ ID NO:1076.

Prior to examination on the merits, please amend the application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.